Prof. Dr. rer. nat. Volker Schirrmacher
Wissenschaftlicher Leiter der Tumorimmunologie am IOZK
Krebsforscher und Immunologe
Prof. Dr. rer. nat. Volker Schirrmacher erhielt 1976 einen Ruf an das Deutsche Krebsforschungszentrum (DKFZ) in Heidelberg als Wissenschaftlicher Rat und Professor für Immunologie. 1979 habilitierte er sich in Immunologie in Heidelberg und 1986 wurde er ordentlicher Professor. Am DKFZ leitete er die Abteilung zelluläre Immunologie bis zu seiner Emeritierung 2008.
Seit 2008 ist er am IOZK Wissenschaftlicher Leiter der Tumorimmunologie. Sein Wissenschaftliches Œuvre umfasst fast 400 Veröffentlichungen in internationalen Fachzeitschriften.
1987 und 1988 war er Vorsitzender der Sektion Experimentelle Krebsforschung bei der Deutschen Krebsgesellschaft und 1989/80 Präsident der Metastasis Research Society. 2003 und 2004 vertrat er Deutschland bei der European Association of Cancer Research (EACR). Von 2009 bis 2011 war er Präsident der Europäischen Gesellschaft für Angewandte Immunologie e.V. (EGAI).
1982 erhielt er den Aronson-Preis und den Meyenburg-Preis und 1988 den Deutschen Krebspreis.
Er ist ein international anerkannter Pionier der Immuntherapie bei Krebs mit dem Schwerpunkt onkolytische Viren. Gemeinsam mit den Naturwissenschaftlern und Ärzten am IOZK arbeitet er an der systematischen Integration neuer wissenschaftlicher Erkenntnisse zur Weiterentwicklung der IOZK-Immuntherapie.
„Viren sind als Auslöser verschiedener Krankheiten bekannt. Weniger bekannt ist jedoch, dass bestimmte Viren für die Behandlung von Krebs eingesetzt werden. Vor über 100 Jahren beobachteten Ärzte erstmals, dass Patienten nach Virusinfektionen von ihrem Krebsleiden geheilt waren.“
Prof. Dr. rer. nat. Volker Schirrmacher
Sammlung: Wissenschaftliche Beiträge und internationale Publikationen von Volker Schirrmacher
Weitere Informationen zu diesem Thema:
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
Interview mit Prof. Dr. Volker Schirrmacher im Klassik Radio
/in IOZK Aktuelles, IOZK In der PresseIndividualized Multimodal Immunotherapy (IMI): Scientific Rationale and Clinical Experience from a Single Institution
/in International Publications, IOZK Aktuelles, IOZK VeröffentlichungenMethods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen, Newcastle Disease VirusDendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Aktuelles, IOZK VeröffentlichungenThe Application of Evidence-Based Medicine in Individualized Medicine
/in International Publications, IOZK VeröffentlichungenIndividualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
/in Dendritic Cells, Glioblastoma, International Publications, IOZK VeröffentlichungenCounteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy
/in International Publications, IOZK VeröffentlichungenSynergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusRandomized Controlled Immunotherapy Clinical Trials for GBM Challenged
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusMitochondria at Work: New Insights into Regulation and Dysregulation of Cellular Energy Supply and Metabolism
/in International Publications, IOZK VeröffentlichungenEvidence-Based Medicine in Oncology: Commercial Versus Patient Benefit
/in International Publications, IOZK VeröffentlichungenPosition paper: new insights into the immunobiology and dynamics of tumor-host interactions require adaptations of clinical studies
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusIOZK Analyse belegt gute Verträglichkeit der IOZK Immuntherapie beim Diffusen intrinsischen pontinen Gliom (DIPG)
/in IOZK VeröffentlichungenAddition of Multimodal Immunotherapy to Combination Treatment Strategies for Children with DIPG: A Single Institution Experience
/in Brain Tumors in Children, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusProf. Dr. Volker Schirrmacher veröffentlicht zwei wegweisende Übersichtsartikel zur Immuntherapie
/in IOZK In der Presse, IOZK VeröffentlichungenCancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis
/in International Publications, IOZK VeröffentlichungenNew Insights into Mechanisms of Long-term Protective Anti-tumor Immunity Induced by Cancer Vaccines Modified by Virus Infection
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusBreaking Therapy Resistance: An Update on Oncolytic Newcastle Disease Virus for Improvements of Cancer Therapy
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusProfessor Volker Schirrmacher vom Kölner IOZK eröffnet die Tagung an der Universität zu Kiel mit seinem Vortrag zur Erforschung onkolytischer Viren im Zusammenhang der individuellen Krebs-Immuntherapie.
/in IOZK bei FachtagungenFrom chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
/in International Publications, IOZK VeröffentlichungenInternational Journal of Oncology: „Von der Chemotherapie zur biologischen Therapie“, Prof. Dr. Volker Schirrmacher
/in IOZK In der Presse, IOZK VeröffentlichungenIOZK-Artikel über Heilversuche bei Glioblastom im Fachorgan: „Austin Oncology Case Report“
/in IOZK VeröffentlichungenIOZK Vortrag: Modulierte Elektro-Hyperthermie bei Kindern mit DIPG, Konferenz der ESHO, Charité Berlin
/in IOZK bei Fachtagungen, IOZK MeldungenBuch Veröffentlichung von Prof. Dr. Schirrmacher: Quo vadis cancer therapy
/in IOZK Meldungen, IOZK VeröffentlichungenIOZK Artikel im International Journal of Molecular Sciences von Prof. Schirrmacher über die Rolle des Newcastle Disease Virus im Rahmen der Tumorimpfung,
/in IOZK In der Presse, IOZK VeröffentlichungenImmunobiology of Newcastle Disease Virus and Its Use for Prophylactic Vaccination in Poultry and as Adjuvant for Therapeutic Vaccination in Cancer Patients
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusIOZK Artikel von Prof. Schirrmacher in „Deutsche Zeitschrift für Onkologie“ über die Grundlagen der Immuntherapie
/in IOZK In der Presse, IOZK VeröffentlichungenIOZK Artikel im Austin Oncology Case Reports über Krebsimpfstoffe
/in IOZK In der Presse, IOZK VeröffentlichungenArtikel von Prof Schirrmacher in Biomedicines: „Fifty Years of Clinical Application of Newcastle Disease Virus“
/in IOZK Meldungen, IOZK VeröffentlichungenFachbeitrag von Prof. Schirrmacher zur Effizienz und Effektivität der Krebsbehandlung, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK VeröffentlichungenExpertenbericht von Prof. Dr. Schirrmacher, Wiener klinisches Magazin
/in IOZK In der Presse, IOZK VeröffentlichungenBericht von Prof. Dr. Schirrmacher im International Journal of Oncology zu den Erkenntnissen der Tumor-reaktiven T-Zell-Memory im Knochenmark
/in IOZK VeröffentlichungenOncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusIOZK Fallstudie zum Langzeitüberleben einer Patientin mit Brustkrebs
/in IOZK Meldungen, IOZK VeröffentlichungenBeitrag von Prof. Dr. Schirrmacher in der Wiener medizinischen Wochenschrift „Skriptum“
/in IOZK In der Presse, IOZK VeröffentlichungenLong-term survival of a breast cancer patient with extensive liver metastases upon immune and virotherapy: a case report
/in Breast Cancer, Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusProf. Dr. Schirrmacher veröffentlicht E-Book: Harnessing Oncolytic Virus-mediated Antitumor Immunity
/in IOZK Meldungen, IOZK VeröffentlichungenStrong T‑cell costimulation can reactivate tumor antigen‑specific T cells in late‑stage metastasized colorectal carcinoma patients: results from a phase Ⅰ clinical study
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusLong-term remission of prostate cancer with extensive bone metastases upon immuno- and virotherapy: A case report
/in Dendritic Cells, Hyperthermia, International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus, Prostate CancerMultimodal cancer therapy involving oncolytic newcastle disease virus, autologous immune cells, and bi-specific antibodies
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusAutologous tumor cell vaccines for post-operative active-specific immunotherapy of colorectal carcinoma: long-term patient survival and mechanism of function
/in Colorectal Cancer, Dendritic Cells, International Publications, IOZK VeröffentlichungenOncolytic Newcastle Disease Virus as Cutting Edge between Tumor and Host
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusBispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusAnalysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusNewcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusImportance of retinoic acid-inducible gene I and of receptor for type I interferon for cellular resistance to infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusImportant role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusTargeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusAntitumor vaccination by Newcastle Disease Virus Hemagglutinin-Neuraminidase plasmid DNA application: changes in tumor microenvironment and activation of innate anti-tumor immunity
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusTranscriptome analysis and cytokine profiling of naive T cells stimulated by a tumor vaccine via CD3 and CD25
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusOptimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusThe hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusPolarization of human monocyte-derived dendritic cells to DC1 by in vitro stimulation with Newcastle Disease Virus
/in Dendritic Cells, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusActivation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusExpression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusCross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusRandomized clinical studies of anti-tumor vaccination: state of the art in 2008
/in Dendritic Cells, International Publications, IOZK VeröffentlichungenNewcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusTreatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study
/in Breast Cancer, Dendritic Cells, International Publications, IOZK VeröffentlichungenActivation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusRecombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusDetection and functional analysis of tumor infiltrating T-lymphocytes (TIL) in liver metastases from colorectal cancer
/in Colorectal Cancer, International Publications, IOZK VeröffentlichungenEfficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial
/in Colorectal Cancer, International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusAn effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusSecond International Conference on Cancer Vaccines/Adjuvants/Delivery for the Next Decade (CVADD): Heidelberg, Germany, 10-12 October 2007
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease VirusHost mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application
/in International Publications, Newcastle Disease VirusRecombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy
/in International Publications, Newcastle Disease VirusRole of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma
/in International Publications, Pancreatic CancerTumor infiltrating T lymphocytes in colorectal cancer: Tumor-selective activation and cytotoxic activity in situ
/in Colorectal Cancer, International PublicationsTumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence
/in International Publications, Newcastle Disease VirusA tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes
/in International Publications, Newcastle Disease VirusTumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein
/in International Publications, Newcastle Disease VirusT-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
/in International Publications, Newcastle Disease VirusSelective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
/in International Publications, Newcastle Disease VirusSelective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein
/in International Publications, Newcastle Disease VirusAntitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells
/in International Publications, Newcastle Disease VirusClinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: improvement of patient survival based on improved antitumor immune memory
/in International Publications, Newcastle Disease VirusAntitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease VirusHigh cell surface expression of Newcastle disease virus proteins via replicon vectors demonstrates syncytia forming activity of F and fusion promotion activity of HN molecules
/in International Publications, Newcastle Disease VirusImportance of serine 200 for functional activities of the hemagglutinin-neuraminidase protein of Newcastle Disease Virus
/in International Publications, Newcastle Disease VirusTNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle disease virus
/in International Publications, Newcastle Disease VirusCognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
/in Breast Cancer, Dendritic Cells, International PublicationsInfluence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
/in Breast Cancer, International PublicationsEditorial von Prof. Dr. Volker Schirrmacher zum Beitrag „Immuntherapeutische Strategien zur Behandlung solider Tumoren“
/in IOZK VeröffentlichungenHuman tumor cell infection by Newcastle Disease Virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis
/in Breast Cancer, Colorectal Cancer, Glioblastoma, International Publications, Newcastle Disease VirusBeitrag mit Prof. Dr. Schirrmacher über den Stellenwert der Dendritischen Zellen im Einsatz gegen Krebszellen
/in Externe Meldungen, IOZK In der PresseGeneration of dendritic cells from human bone marrow mononuclear cells: advantages for clinical application in comparison to peripheral blood monocyte derived cells
/in Dendritic Cells, International PublicationsAntitumor effects of Newcastle Disease Virus in vivo: local versus systemic effects
/in International Publications, Newcastle Disease VirusTumor stimulator cell modification by infection with Newcastle Disease Virus: analysis of effects and mechanism in MLTC-CML cultures
/in International Publications, Newcastle Disease VirusHuman tumor cell modification by virus infection: an efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus
/in International Publications, Newcastle Disease VirusIntroduction of adhesive and costimulatory immune functions into tumor cells by infection with Newcastle Disease Virus
/in International Publications, Newcastle Disease VirusTumor-cell number and viability as quality and efficacy parameters of autologous virus-modified cancer vaccines in patients with breast or ovarian cancer
/in Breast Cancer, International Publications, Newcastle Disease Virus, Ovarian Cancer